7 Undervalued Pharmaceuticals Stocks for Wednesday, October 16
Discover the top 7 undervalued Pharmaceuticals stocks for Wednesday, October 16 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.
Commentary & Analysis
4 Undervalued Pharmaceuticals Stocks for Friday, September 13
Discover the top 4 undervalued Pharmaceuticals stocks for Friday, September 13 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Pharmaceuticals Stocks for Tuesday, July 02
Discover the top 7 undervalued Pharmaceuticals stocks for Tuesday, July 02 based on AAII’s Stock Grades.Grace Malone
7 Undervalued Pharmaceuticals Stocks for Wednesday, May 15
Discover the top 7 undervalued Pharmaceuticals stocks for Wednesday, May 15 based on AAII’s Stock Grades.Jenna Brashear
6 Undervalued Pharmaceuticals Stocks for Tuesday, October 10
Discover the top 6 undervalued Pharmaceuticals stocks for Tuesday, October 10 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | YCBD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.2 | $583.5 | 4% |
|
| Shares Out (Mil) | 10.6 | 43.1 | 21% |
|
| Institutional Ownership | 86.0% | 83.7% | 54% |
|
| Float (Mil) | 10.9 | 45.1 | 20% |
|
| Beta | 2.17 | 0.73 | 94% |
|
| Avg Daily Volume (000s) | 262 | 316 | 49% |
|
| Price Change (52-week) |
(30.6%) | 64.1% | 27% |
|
| Growth | YCBD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (14.5%) | 6.7% | 3% |
|
| Net Income (5yr) | (16.6%) | (1.4%) | 24% |
|
| EPS (5yr) | (15.0%) | 15.1% | 18 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.0%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | YCBD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $21 | $317 | 13% |
|
| Net Income (TTM) (Mil) | ($3) | ($11) | 35% |
|
| EPS (TTM) | ($0.316) | ($0.700) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($6) | 28% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $5 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | $6 | $508 | 6% |
|
| Valuation | YCBD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.63 | 2.57 | 11% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | YCBD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.7% | 69.4% | 70% |
|
| Net Margin | (13.8%) | 0.8% | 19% |
|
| ROA | (25.1%) | (22.5%) | 18% |
|
| ROE | (40.3%) | (21.8%) | 17% |
|
| Liabilities to Assets | 37.5% | 32.5% | 28% |
|
| F-Score | 3 | 3 | 18% |
|
cbdMD, Inc. did not pass any screens on 9/16/2026.
